⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LTRN News
Lantern Pharma Inc. Common Stock
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
businesswire.com
LTRN
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report
businesswire.com
LTRN
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001
businesswire.com
LTRN
RedChip AI Investor Conference Replays Now Available Highlighting Companies Driving Innovation Across the AI Ecosystem
accessnewswire.com
ZEO
SHAZ
LTRN
CSAI
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET
businesswire.com
LTRN
New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST
accessnewswire.com
CAST
LTRN
VRTX
NRXP
DVLT
RDZN
SDST
CISO
RedChip Highlights Public Companies Advancing the Next Phase of AI Adoption at Virtual Investor Conference on March 19
accessnewswire.com
SHAZ
LTRN
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
prnewswire.com
AVBP
SMMT
MRUS
MRK
GNPX
CGEM
ABBV
BMY
BDTX
LTRN
PFE
JNJ
LLY
Lantern Pharma to Present at the 7 th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
businesswire.com
LTRN
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
businesswire.com
LTRN